Savannah Eden Greyrose Baril, MD
Ophthalmology · Camarillo
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 17 years
- Duke University School of Medicine, 2009
Offices
2 locations · Miramar Eye Specialists Medical Group Inc · Eghbali Medical Surgical Inc
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Baril’s office to ask if they take your plan before you enroll.
Original Medicare doctor bills
$5,330
Medicare paid this office $5,330 for 34 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Established patient problem focused exam of visual system | 33 | $3,029 | $74 |
Who their Medicare patients are
34 Original Medicare patients in 2024. Average age 78 · Under 65 0% · Women 65% · Health risk score 1.16. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 71% · Diabetes 38% · Coronary heart disease 38%.
The office billed $14,795, Medicare allowed $7,246 and paid $5,330; for 54 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 34 | 54 | 78 | 1.16 | $14,795 | $5,330 |
| 2023 | 39 | 63 | 78 | 1.08 | $27,200 | $9,055 |
| 2022 | 37 | 90 | 76 | 1.09 | $26,406 | $10,406 |
| 2021 | 31 | 68 | 76 | 0.88 | $23,075 | $8,633 |
| 2019 | 27 | 70 | 78 | 1.06 | $11,950 | $7,760 |
| 2018 | 40 | 96 | 77 | 1.09 | $18,487 | $11,097 |
| 2017 | 158 | 635 | 75 | 1.29 | $125,457 | $42,309 |
| 2016 | 125 | 306 | 75 | 1.13 | $89,668 | $33,343 |
| 2014 | 66 | 80 | 66 | 1.95 | $29,869 | $8,442 |
| 2013 | 69 | 89 | 67 | 2.33 | $38,605 | $10,428 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Established patient problem focused exam of visual system | 28 | $3,092 | $75 |
2022: 1 service
| Established patient problem focused exam of visual system | 28 | $4,067 | $78 |
2021: 1 service
| Established patient problem focused exam of visual system | 30 | $3,522 | $80 |
2019: 2 services
| Return visit (30+ min) | 16 | $1,802 | $86 |
| Established patient problem focused exam of visual system | 15 | $1,369 | $72 |
2018: 1 service
| Established patient problem focused exam of visual system | 28 | $2,886 | $72 |
2017: 11 services
| Established patient problem focused exam of visual system | 109 | $9,080 | $66 |
| Short return visit (20+ min) | 35 | $2,435 | $61 |
| Insertion of probe into nasal tear duct | 12 | $2,124 | $177 |
| Established patient complete exam of visual system | 15 | $1,440 | $90 |
| New patient complete exam of visual system | 13 | $1,395 | $107 |
| Short return visit | 35 | $1,362 | $32 |
| New patient problem focused exam of visual system | 14 | $988 | $71 |
| Exam of visual field with extended testing | 17 | $959 | $56 |
| Photography of content of eyes | 47 | $888 | $17 |
| Exam of visual field with limited testing | 21 | $677 | $28 |
| Exam to measure eye deviation and range of motion | 11 | $605 | $55 |
2016: 3 services
| Established patient problem focused exam of visual system | 105 | $12,222 | $75 |
| Established patient complete exam of visual system | 12 | $1,518 | $108 |
| Photography of content of eyes | 22 | $431 | $18 |
2014: 1 service
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $2,793 | $103 |
2013: 1 service
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 48 | $4,979 | $104 |
Drugs they prescribed that Part D paid
$126
Pharmacies billed $126 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
14 generic and 0 brand-name prescriptions · $126 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 14 | None | None | 0% | $126 |
| 2023 | 186 | 62 | 12% (22) | None | $2,808 |
| 2022 | 163 | 64 | 18% (29) | None | $2,262 |
| 2021 | 56 | 40 | None | None | $1,207 |
| 2020 | 126 | 56 | 15% (19) | 10% | $4,120 |
| 2019 | 153 | 76 | 16% (25) | None | $2,500 |
| 2018 | 202 | 85 | 6% (13) | 8% | $4,783 |
| 2017 | 82 | 36 | None | 15% | $3,259 |
| 2016 | 69 | 34 | None | 25% | $3,843 |
| 2015 | 116 | 58 | 32% (37) | 9% | $2,920 |
| 2014 | 171 | 91 | 26% (45) | 19% | $5,876 |
| 2013 | 125 | 41 | 0% (0) | 67% | $8,690 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Erythromycin | 71 | $1,025 | $14 |
| Neomycin-Polymyxin-Dexameth | 37 | $486 | $13 |
| Methylprednisolone | 16 | $154 | $10 |
| Hydrocodone-Acetaminophen | 22 | $108 | $5 |
2022: 4 drugs
| Erythromycin | 70 | $1,068 | $15 |
| Neomycin-Polymyxin-Dexameth | 25 | $290 | $12 |
| Methylprednisolone | 19 | $189 | $10 |
| Hydrocodone-Acetaminophen | 29 | $154 | $5 |
2021: 1 drug
| Erythromycin | 40 | $497 | $12 |
2020: 2 drugs
| Erythromycin | 66 | $840 | $13 |
| Hydrocodone-Acetaminophen | 19 | $49 | $3 |
2019: 3 drugs
| Erythromycin | 88 | $1,025 | $12 |
| Methylprednisolone | 12 | $190 | $16 |
| Hydrocodone-Acetaminophen | 24 | $52 | $2 |
2018: 4 drugs
| Erythromycin | 101 | $1,002 | $10 |
| Methylprednisolone | 32 | $414 | $13 |
| Doxycycline Hyclate | 12 | $352 | $29 |
| Neomycin-Polymyxin-Dexameth | 13 | $176 | $14 |
2017: 2 drugs
| Doxycycline Hyclate | 27 | $1,205 | $45 |
| Erythromycin | 21 | $240 | $11 |
2016: 2 drugs
| Erythromycin | 24 | $268 | $11 |
| Neomycin-Polymyxin-Dexameth | 12 | $220 | $18 |
2015: 4 drugs
| Hydrocodone-Acetaminophen | 19 | $522 | $27 |
| Methylprednisolone | 25 | $502 | $20 |
| Erythromycin | 16 | $177 | $11 |
| Lorazepam | 12 | $40 | $3 |
2014: 5 drugs
| Methylprednisolone | 49 | $979 | $20 |
| Erythromycin | 31 | $295 | $10 |
| Vicodin | 11 | $249 | $23 |
| Hydrocodone-Acetaminophen | 11 | $248 | $23 |
| Acetaminophen-Codeine | 16 | $50 | $3 |
2013: 6 drugs
| Nevanac | 11 | $1,811 | $165 |
| Vigamox | 17 | $1,738 | $102 |
| Dorzolamide-Timolol | 12 | $486 | $40 |
| Prednisolone Acetate | 25 | $376 | $15 |
| Latanoprost | 13 | $197 | $15 |
| Erythromycin | 12 | $190 | $16 |
Money from drug and device companies
$244 in 2025
| 2025 | 4 | 6 | None | $244 |
| 2024 | 2 | 2 | None | $41 |
| 2023 | 4 | 5 | None | $263 |
| 2022 | 3 | 5 | None | $389 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Healthcare Solutions | Eylea Hd | $125 | 1 payment
|
| Tarsus Pharmaceuticals | Xdemvy | $71 | 3 payments
|
| Abbvie | Lumigan | $30 | 1 payment
|
| Bausch & Lomb Americas | Miebo | $19 | 1 payment
|
See all 6 published payments
| Abbvie | Meals · 2025-11-14 | Lumigan | $30 |
| Tarsus Pharmaceuticals | Meals · 2025-10-04 | Xdemvy | $22 |
| Bausch & Lomb Americas | Meals · 2025-06-12 | Miebo | $19 |
| Tarsus Pharmaceuticals | Meals · 2025-05-20 | Xdemvy | $26 |
| Tarsus Pharmaceuticals | Meals · 2025-03-21 | Xdemvy | $24 |
| Regeneron Healthcare Solutions | Meals · 2025-03-17 | Eylea Hd | $125 |
See earlier years (2024, 2023, 2022)
2024: $41
| Amgen | Tepezza | $24 | 1 payment
|
| Abbvie | Lumigan | $17 | 1 payment
|
2023: $263
| Medtronic | Endurant Iis | $172 | 1 payment
|
| AbbVie | Lumigan | $45 | 2 payments
|
| Sun Pharmaceutical Industries | Cequa | $24 | 1 payment
|
| Horizon Therapeutics plc | Tepezza | $23 | 1 payment
|
2022: $389
| W. L. Gore & Associates | Gore Tag Conformable Thoracic Endoprosthesis | $179 | 1 payment
|
| Boston Scientific | General - Vascular Intervention | $146 | 1 payment
|
| Horizon Therapeutics plc | Tepezza | $63 | 3 payments
|
Professional record
- NPI
- 1235372905
- Licence
- MA MT195272
- Trained
- Duke University School of Medicine, 2009 · 17 years ago
- Group
- Miramar Eye Specialists Medical Group Inc · Eghbali Medical Surgical Inc
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- Po Box 103010, Pasadena, CA, 91189
- NPI first listed
- 2009-04-10
- NPI last updated
- 2025-03-04
- NPI record certified
- 2025-03-04
This is when the NPI record was last certified, not a medical board exam.